Stockscreener 앱 받기
4.78
16.02%
0.66
시간 외 거래:
4.76
-0.02
-0.42%
전일 마감가:
$4.12
열려 있는:
$4.16
하루 거래량:
66.88M
Relative Volume:
3.42
시가총액:
$2.56B
수익:
$66.41M
순이익/손실:
$-559.78M
주가수익비율:
-3.976
EPS:
-1.2022
순현금흐름:
$-328.09M
1주 성능:
+29.19%
1개월 성능:
+31.68%
6개월 성능:
+53.70%
1년 성능:
-12.93%
1일 변동 폭
$4.0601
$4.935
1주일 범위
$3.7225
$4.935
52주 변동 폭
$2.77
$7.18
리커젼 파마 Stock (RXRX) Company Profile
명칭
Recursion Pharmaceuticals Inc
전화
(385) 269-0203
주소
41S RIO GRANDE STREET, SALT LAKE CITY
Compare RXRX vs VRTX, MRNA, REGN, ARGX, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
RXRX
Recursion Pharmaceuticals Inc
|
4.78 | 2.01B | 66.41M | -559.78M | -328.09M | -1.2022 |
VRTX
Vertex Pharmaceuticals Inc
|
503.50 | 127.93B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
203.21 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
726.47 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
912.87 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
207.68 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
리커젼 파마 Stock (RXRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-17 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2025-07-03 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-05-22 | 개시 | Morgan Stanley | Equal-Weight |
| 2023-03-16 | 개시 | Needham | Buy |
| 2022-09-16 | 개시 | KeyBanc Capital Markets | Overweight |
| 2022-04-18 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-03-04 | 다운그레이드 | SVB Leerink | Outperform → Mkt Perform |
| 2021-09-21 | 개시 | Berenberg | Buy |
| 2021-05-11 | 개시 | BofA Securities | Buy |
| 2021-05-11 | 개시 | Goldman | Neutral |
| 2021-05-11 | 개시 | JP Morgan | Neutral |
| 2021-05-11 | 개시 | KeyBanc Capital Markets | Overweight |
| 2021-05-11 | 개시 | SVB Leerink | Outperform |
모두보기
리커젼 파마 주식(RXRX)의 최신 뉴스
Recursion Pharmaceuticals (RXRX) Registers a Bigger Fall Than the Market: Important Facts to Note - Yahoo Finance
RXRX Stock Soars Pre-Market On Q4 Beat, Recursion CEO Says Company Has ‘Reached An Inflection Point’ - Stocktwits
RXRX Stock Rises As Tempus AI Deal Resets Growth Story - StocksToTrade
Can Recursion Pharmaceuticals' Strategic Deals Fuel Long-Term Growth? - TradingView
Recursion Pharmaceuticals (RXRX) Short Interest & Short Float | Updated Sep 2026 $RXRX - MarketBeat
Recursion Pharmaceuticals, Inc. (RXRX) stock price, news, quote and history - Yahoo Finance UK
Recursion Pharmaceuticals (RXRX) Shares Just Moved, So What Is Driving Attention Now? - Simply Wall Street
Recursion Pharmaceuticals (RXRX) Stock Moves 2.02%: What You Should Know - Yahoo Finance
RXRX Extends Tempus Deal As Stock Climbs On Predictable Cash - timothysykes.com
Recursion Pharmaceuticals, Inc. (RXRX) Stock Analysis: High Potential Upside in the Biotech Sector - DirectorsTalk Interviews
RXRX Stock Grinds Higher As Insider Filings Stack Up - timothysykes.com
A data partnership shifts from potential $84 million in two-year fees to $42 million in committed payments over three - Stock Titan
Recursion Pharmaceuticals (NASDAQ: RXRX) Lowers Tempus Annual Fees to $14 Million - Kalkine Media
Recursion Pharmaceuticals, Inc. Grants Tempus Ai, Inc. Non-Exclusive License for Rna Foundation Model - marketscreener.com
Recursion, Tempus Expand AI and RNA Collaboration Agreements - TipRanks
Recursion Resets Tempus Data Pact and Licenses TxFM RNA Model in $12M Deal - TradingView
Recursion Pharmaceuticals Enters Amendment To Master Agreement With Tempus On Sept 15, 2026SEC Filing - TradingView
Recursion Pharmaceuticals Highlights AI Drug Platform, FAP Progress at Morgan Stanley Conference - Yahoo Finance
Is Recursion Pharmaceuticals (RXRX) A Bargain As Its Shares Rebound? - Yahoo Finance
Recursion Pharmaceuticals Inc (RXRX) Stock Price, Quote, News & History - Benzinga
RXRX Stock Holds Support As Insider Form 4s Hit Tape - StocksToTrade
RXRX Stock Steadies As Insider Activity Draws Trader Focus - timothysykes.com
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives Average Rating of "Hold" from Analysts - MarketBeat
Recursion Pharmaceuticals, Inc. (RXRX) Options ChainYahoo Finance - Yahoo! Finance Canada
RXRX Stock Holds Steady As Insider Form 4 Filings Stack Up - timothysykes.com
Recursion Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript - Benzinga
Recursion Pharmaceuticals (RXRX): Can Its AI Platform Translate Into Clinical Wins? - RTTNews
Recursion Pharmaceuticals (RXRX) CFO’s 5,396-share move wasn’t a sale - Stock Titan
Recursion Pharmaceuticals (RXRX) Falls More Steeply Than Broader Market: What Investors Need to Know - finance.yahoo.com
Recursion Pharmaceuticals Stock (RXRX) Opinions on Recent Conference Updates and Partnerships - Moomoo
Recursion at Morgan Stanley conference: AI platform moves into clinic - Investing.com
Recursion Pharma CEO Najat Khan sells $78,822 in stock By Investing.com - Investing.com South Africa
Recursion Pharmaceuticals (RXRX) CEO and President Najat Khan Sells 22,408 Shares - GuruFocus
Recursion Pharma CEO Najat Khan sells $78,822 in stock - investing.com
Recursion Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer Khan Najat - Moomoo
Recursion Pharmaceuticals CEO Najat Khan Sells 22,408 Shares Under 10b5-1 Plan - Kalkine Media
Recursion Pharmaceuticals (NASDAQ:RXRX) Trades Active As Small-Caps Wobble - Kalkine Media
Recursion (NASDAQ: RXRX) CEO sells 22K shares under preset plan - Stock Titan
Why Recursion Pharmaceuticals (RXRX) Dipped More Than Broader Market Today - Yahoo Finance
Recursion Pharmaceuticals Tokenized Stock (Ondo) price today, RXRXon to USD live price, marketcap and chart - CoinMarketCap
Recursion Pharmaceuticals Stock Short Interest Falls to 34.79% - Moomoo
Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144 - Moomoo
2 Beaten-Down Stocks to Avoid Right Now - theglobeandmail.com
Recursion (NASDAQ: RXRX) officer moves to sell stock - Stock Titan
AI in Pharmaceutical Market to Hit USD 48.43 Billion by 2035, Growing at 31.76% CAGR – SNS Insider - GlobeNewswire Inc.
Penny Stocks To ResearchSeptember 6th - MarketBeat
Penny Stocks To Follow NowSeptember 5th - MarketBeat
RXRX Tightens Spending As AI Drug Platform Gains Traction - timothysykes.com
RXRX Tightens Cash Burn As AI Drug Pipeline Advances - StocksToTrade
RXRX Tightens Costs As AI Drug Pipeline Advances - timothysykes.com
Why Is Recursion Pharmaceuticals (RXRX) Up 8.2% Since Last Earnings Report? - Yahoo Finance
리커젼 파마 (RXRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.76%
0.87%
자본화:
|
볼륨(24시간):